{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:25:36Z","timestamp":1779128736581,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB216037"],"award-info":[{"award-number":["20232BAB216037"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160405"],"award-info":[{"award-number":["82160405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160038"],"award-info":[{"award-number":["82160038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260035"],"award-info":[{"award-number":["82260035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00011-023-01839-4","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T03:02:15Z","timestamp":1704855735000},"page":"329-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CD8\u2009+\u2009T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia"],"prefix":"10.1007","volume":"73","author":[{"given":"Fangmin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiajing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"L Newell","year":"2021","unstructured":"Newell L, Cook R. Advances in acute myeloid leukemia. BMJ (Clin Res ed). 2021;375:n2026. https:\/\/doi.org\/10.1136\/bmj.n2026.","journal-title":"BMJ (Clin Res ed)"},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1716863.","journal-title":"N Engl J Med"},{"key":"1839_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196:316\u201328. https:\/\/doi.org\/10.1111\/bjh.17746.","journal-title":"Br J Haematol"},{"key":"1839_CR4","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363. https:\/\/doi.org\/10.1038\/s41375-021-01253-x.","journal-title":"Leukemia"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123:356\u201365. https:\/\/doi.org\/10.1182\/blood-2013-08-523548.","journal-title":"Blood"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374. https:\/\/doi.org\/10.1038\/s41375-018-0180-3.","journal-title":"Leukemia"},{"key":"1839_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333. https:\/\/doi.org\/10.1016\/j.blre.2018.10.003.","journal-title":"Blood Rev"},{"key":"1839_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051241","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Emerging CAR T cell strategies for the treatment of AML. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14051241.","journal-title":"Cancers (Basel)."},{"key":"1839_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142249","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11142249.","journal-title":"Cells"},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Current Biol. 2020;30:R921-r925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081.","journal-title":"Current Biol"},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20:218\u201332. https:\/\/doi.org\/10.1038\/s41568-019-0235-4.","journal-title":"Nat Rev Cancer"},{"key":"1839_CR12","doi-asserted-by":"publisher","first-page":"715234","DOI":"10.3389\/fimmu.2021.715234","volume":"12","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8(+) T cell exhaustion in cancer. Front Immunol. 2021;12:715234. https:\/\/doi.org\/10.3389\/fimmu.2021.715234.","journal-title":"Front Immunol"},{"key":"1839_CR13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3389\/fimmu.2018.01810","volume":"9","author":"AB Morris","year":"2018","unstructured":"Morris AB, Adams LE, Ford ML. Influence of T cell coinhibitory molecules on CD8(+) recall responses. Front Immunol. 2018;9:1810. https:\/\/doi.org\/10.3389\/fimmu.2018.01810.","journal-title":"Front Immunol"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470\u201381. https:\/\/doi.org\/10.1002\/cncr.31896.","journal-title":"Cancer"},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114:3909\u201316. https:\/\/doi.org\/10.1182\/blood-2009-02-206946.","journal-title":"Blood"},{"key":"1839_CR16","doi-asserted-by":"publisher","first-page":"686156","DOI":"10.3389\/fonc.2021.686156","volume":"11","author":"L Xu","year":"2021","unstructured":"Xu L, et al. PD-1 and TIGIT are highly co-expressed on CD8(+) T cells in AML patient bone marrow. Front Oncol. 2021;11:686156. https:\/\/doi.org\/10.3389\/fonc.2021.686156.","journal-title":"Front Oncol"},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","volume":"8","author":"B Jia","year":"2018","unstructured":"Jia B, et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 2018;8:34. https:\/\/doi.org\/10.1038\/s41408-018-0069-4.","journal-title":"Blood Cancer J"},{"key":"1839_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","author":"HA Knaus","year":"2018","unstructured":"Knaus HA, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.120974.","journal-title":"JCI Insight"},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1078-0432.Ccr-19-3003","volume":"26","author":"L Tang","year":"2020","unstructured":"Tang L, et al. Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia. Clin Cancer Res. 2020;26:1763\u201372. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3003.","journal-title":"Clin Cancer Res"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.Ccr-08-3010","volume":"15","author":"MJ Szczepanski","year":"2009","unstructured":"Szczepanski MJ, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325\u201332. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-3010.","journal-title":"Clin Cancer Res"},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","volume":"75","author":"X Wang","year":"2005","unstructured":"Wang X, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;75:468\u201376. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00537.x.","journal-title":"Eur J Haematol"},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116:2484\u201393. https:\/\/doi.org\/10.1182\/blood-2010-03-275446.","journal-title":"Blood"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"L Zhang","year":"2009","unstructured":"Zhang L, Gajewski TF, Kline J. PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545\u201352. https:\/\/doi.org\/10.1182\/blood-2009-03-206672.","journal-title":"Blood"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"A Newman","year":"2015","unstructured":"Newman A, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1078-0432.Ccr-20-3417","volume":"27","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. An immune risk score predicts survival of patients with acute myeloid leukemia receiving chemotherapy. Clin Cancer Res. 2021;27:255\u201366. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3417.","journal-title":"Clin Cancer Res"},{"key":"1839_CR26","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"1839_CR27","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1128","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005. https:\/\/doi.org\/10.2202\/1544-6115.1128.","journal-title":"Stat Appl Genet Mol Biol"},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12:21. https:\/\/doi.org\/10.1186\/s13073-020-0721-z.","journal-title":"Genome Med"},{"key":"1839_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci159579","author":"S Rutella","year":"2022","unstructured":"Rutella S, et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/jci159579.","journal-title":"J Clin Invest"},{"key":"1839_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","author":"W Roh","year":"2017","unstructured":"Roh W, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aah3560.","journal-title":"Sci Transl Med"},{"key":"1839_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3.","journal-title":"Blood Cancer J"},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/jci129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130:1552\u201364. https:\/\/doi.org\/10.1172\/jci129204.","journal-title":"J Clin Invest"},{"key":"1839_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115611.","journal-title":"Annu Rev Immunol"},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1.","journal-title":"Nat Med"},{"key":"1839_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"1839_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"1839_CR39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","volume":"129","author":"Y Abaza","year":"2017","unstructured":"Abaza Y, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275\u201383. https:\/\/doi.org\/10.1182\/blood-2016-09-736686.","journal-title":"Blood"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-023-01839-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T12:06:59Z","timestamp":1708776419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-023-01839-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1007\/s00011-023-01839-4","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}